Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

Author： Taskar Kunal   Rudraraju Vinay   Mittapalli Rajendar   Samala Ramakrishna   Thorsheim Helen   Lockman Julie   Gril Brunilde   Hua Emily   Palmieri Diane   Polli Joseph   Castellino Stephen   Rubin Stephen   Lockman Paul   Steeg Patricia   Smith Quentin  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.29, Iss.3, 2012-03, pp. : 770-781

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lapatinib: A Review of its Use in the Treatment of HER2-Overexpressing, Trastuzumab-Refractory, Advanced or Metastatic Breast Cancer

By Frampton James E.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2125-2148

Adis International

Access to resources Recommend Favorite

Lapatinib no help in HER-2-negative breast cancer

By  

Inpharma, Vol. 1, Iss. 1663, 2008-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

By  

Current Cancer Drug Targets, Vol. 15, Iss. 8, 2015-01 ,pp. : 665-683

Bentham Science Publishers

Access to resources Recommend Favorite

Lapatinib: In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

By Curran Monique P.  

Drugs, Vol. 70, Iss. 11, 2010-07 ,pp. : 1411-1422

Adis International

Access to resources Recommend Favorite

Trastuzumab: A Review of its Use in the Treatment of Metastatic Breast Cancer Overexpressing HER2

By McKeage K.   Perry C.M.  

Drugs, Vol. 62, Iss. 1, 2002-01 ,pp. : 209-243

Adis International

Access to resources Recommend Favorite